Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes

References

• StoutRWInsulin and atheroma: 20-yr perspectiveDiabetes Care19901366316542192848
   PubMed Web of Science ®Google Scholar
• PyoralaMMiettinenHLaaksoMPyoralaKHyperinsulinemia Predicts Coronary Heart Disease Risk in Healthy Middle-aged Men: The 22-Year Follow-up Results of the Helsinki Policemen StudyCirculation19989853984049714089
   PubMed Web of Science ®Google Scholar
• SatoYShiraishiSOshidaYIshiguroTSakamotoNExperimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar ratsDiabetes198938191962642437
   PubMed Web of Science ®Google Scholar
• JosephJJGoldenSHType 2 diabetes and cardiovascular disease: what next?Curr Opin Endocrinol Diabetes Obes201421210912024569552
   PubMedGoogle Scholar
• Stark CasagrandeSFradkinJESaydahSHRustKFCowieCCThe prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010Diabetes Care20133682271227923418368
   PubMed Web of Science ®Google Scholar
• TaylorKSHeneghanCJFarmerAJAll-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large UK Primary Care DatabaseDiabetes Care20133682366237123435157
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRönnemaaTPyöräläKLaaksoMMortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionN Engl J Med199833942292349673301
   PubMed Web of Science ®Google Scholar
• NathanDMClearyPABacklundJYIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetesN Engl J Med2005353252643265316371630
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• ClearyPAOrchardTJGenuthSThe Effect of Intensive Glycemic Treatment on Coronary Artery Calcification in Type 1 Diabetic Participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyDiabetes200655123556356517130504
   PubMed Web of Science ®Google Scholar
• Epidemiology of Diabetes Interventions and Complications Research GroupEffect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Epidemiology of Diabetes Interventions and Complications (EDIC) Research GroupDiabetes199948238339010334318
   PubMed Web of Science ®Google Scholar
• NathanDMLachinJClearyPIntensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitusN Engl J Med2003348232294230312788993
   PubMed Web of Science ®Google Scholar
• PolakJFBacklundJYClearyPAProgression of Carotid Artery Intima-Media Thickness During 12 Years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) StudyDiabetes201160260761321270271
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318548659742977
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ2000321725840541210938048
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study GroupGersteinHCMillerMEEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative GroupPatelAMacMahonSIntensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Engl J Med2008358242560257218539916
   PubMed Web of Science ®Google Scholar
• DuckworthWAbrairaCMoritzTGlucose control and vascular complications in veterans with type 2 diabetesN Engl J Med2009360212913919092145
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2014Diabetes Care201437Suppl 1S14S8024357209
   PubMed Web of Science ®Google Scholar
• RosenstockJDaileyGMassi-BenedettiMFritscheALinZSalzmanAReduced Hypoglycemia Risk With Insulin Glargine A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetesDiabetes Care200528495095515793205
   PubMed Web of Science ®Google Scholar
• The ORIGIN Trial InvestigatorsGersteinHCBoschJBasal Insulin and Cardiovascular and Other Outcomes in DysglycemiaN Engl J Med2012367431932822686416
   PubMed Web of Science ®Google Scholar
• DaviesMJDonnellyRBarnettAHJonesSNicolayCKilcoyneAExenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) studyDiabetes Obes Metab200911121153116219930005
   PubMed Web of Science ®Google Scholar
• RobinsonLEHoltTAReesKRandevaHSO’HareJPEffects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open201331pii:e001986
   Web of Science ®Google Scholar
• WangBZhongJLinHBlood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trialsDiabetes Obes Metab201315873774923433305
   PubMed Web of Science ®Google Scholar
• HortonESSilbermanCDavisKLBerriaRWeight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients with Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort DatabaseDiabetes Care20103381759176520460445
   PubMed Web of Science ®Google Scholar
• ChaudhuriADandonaPEffects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetesDiabetes Obes Metab2011131086987921569185
   PubMed Web of Science ®Google Scholar
• ReynoldsLRKingsleyFJKarounosDGTannockLRDifferential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetesDiabetes Res Clin Pract200777218018717239474
   PubMed Web of Science ®Google Scholar
• BunckMCCornerAEliassonBOne-year treatment with exenatide vs Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stressAtherosclerosis2010212122322920494360
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHKauppinen-MakelinRTiikkainenMInsulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET studyDiabetologia200649344245116456680
   PubMed Web of Science ®Google Scholar
• LiWXGouJFTianJHYanXYangLGlucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trialsCurr Ther Res Clin Exp201071421123824688145
   PubMed Web of Science ®Google Scholar
• SpectreGOstensonCGLiNHjemdahlPPostprandial Platelet Activation is Related to Postprandial Plasma Insulin Rather Than Glucose in Patients with Type 2 DiabetesDiabetes20126192380238422688337
   PubMed Web of Science ®Google Scholar
• YngenMOstensonCGHjemdahlPWallenNHMeal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamideDiabet Med200623213414016433710
   PubMed Web of Science ®Google Scholar
• FormosoGDe FilippisEAMichettiNDecreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjectsDiabetes Metab Res Rev200824323123717966969
   PubMed Web of Science ®Google Scholar
• KhanolkarMPMorrisRHThomasAWRosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus – an effect probably mediated by direct platelet PPARγ activationAtherosclerosis2008197271872417765245
   PubMed Web of Science ®Google Scholar
• SwinnenSGDainMPAronsonRA 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients with Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering DrugsDiabetes Care20103361176117820200301
   PubMed Web of Science ®Google Scholar
• RaskinPGylvinTWengWChaykinLComparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetesDiabetes Metab Res Rev200925654254819565569
   PubMed Web of Science ®Google Scholar
• HollanderPCooperJBregnhøjJPedersenCBA 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetesClin Ther200830111976198719108786
   PubMed Web of Science ®Google Scholar
• RosenstockJDaviesMHomePDLarsenJKoenenCSchernthanerGA randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia200851340841618204830
   PubMed Web of Science ®Google Scholar
• SwinnenSGSimonAHollemanFHoekstraJBDeVriesJHInsulin detemir versus insulin glargine for type 2 diabetes mellitusCochrane Database Syst Rev20117CD00638321735405
   PubMed Web of Science ®Google Scholar
• BazzanoLALeeLJShiLReynoldsKJacksonJAFonsecaVSafety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trialsDiabet Med200825892493218959605
   PubMed Web of Science ®Google Scholar
• DesouzaCSalazarHCheongBMurgoJFonsecaVAssociation of Hypoglycemia and Cardiac Ischemia A study based on continuous monitoringDiabetes Care20032651485148912716809
   PubMed Web of Science ®Google Scholar
• MarquesJLGeorgeEPeaceySRAltered ventricular repolarization during hypoglycaemia in patients with diabetesDiabet Med19971486486549272590
   PubMed Web of Science ®Google Scholar
• RobinsonRTHarrisNDIrelandRHMacdonaldIAHellerSRChanges in cardiac repolarization during clinical episodes of nocturnal hypogly caemia in adults with Type 1 diabetesDiabetologia200447231231514712347
   PubMed Web of Science ®Google Scholar
• GillGVWoodwardACassonIFWestonPJCardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes – the ‘dead in bed’ syndrome revisitedDiabetologia2009521424518972096
   PubMed Web of Science ®Google Scholar
• TsujimotoTYamamoto-HondaRKajioHVital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patientsDiabetes Care201437121722523939540
   PubMed Web of Science ®Google Scholar
• ZoungasSPatelAChalmersJSevere hypoglycemia and risks of vascular events and deathN Engl J Med2010363151410141820925543
   PubMed Web of Science ®Google Scholar
• BondsDEMillerMEBergenstalRMThe association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD studyBMJ2010340b490920061358
   PubMed Web of Science ®Google Scholar
• SchernthanerGDiabetes and Cardiovascular Disease: is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGARWien Med Wochenschr20101601–281920229156
   PubMedGoogle Scholar
• BoucaiLSouthernWNZonszeinJHypoglycemia-associated Mortality is Not Drug-associated but Linked to ComorbiditiesAm J Med2011124111028103522017781
   PubMed Web of Science ®Google Scholar
• YakubovichNGersteinHCSerious Cardiovascular Outcomes in Diabetes: The Role of HypoglycemiaCirculation2011123334234821263007
   PubMed Web of Science ®Google Scholar
• GotoAArahOAGotoMTerauchiYNodaMSevere hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysisBMJ2013347f453323900314
   PubMed Web of Science ®Google Scholar
• GrudenGBaruttaFChaturvediNSevere Hypoglycemia and Cardiovascular Disease Incidence in Type 1 Diabetes: The EURODIAB Prospective Complications StudyDiabetes Care20123571598160422584135
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial Research GroupHypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research GroupDiabetes19974622712869000705
   PubMed Web of Science ®Google Scholar
• NathanDMBaylessMClearyPDiabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and ContributionsDiabetes201362123976398624264395
   PubMed Web of Science ®Google Scholar
• RatnerREHirschIBNeifingJLGargSKMeccaTEWilsonCALess hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 DiabetesDiabetes Care200023563964310834423
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHDresslerAZiemenMHOE 901/300s Study GroupLess nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetesDiabetes Care20002381130113610937510
   PubMed Web of Science ®Google Scholar
• HongJZhangYLaiSEffects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery DiseaseDiabetes Care20133651304131123230096
   PubMed Web of Science ®Google Scholar
• SelvinEBolenSYehHCCardiovascular outcomes in trials of oral diabetes medications: a systematic reviewArch Intern Med2008168192070208018955635
   PubMedGoogle Scholar
• JuhaeriJGaoSDaiWSIncidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulinPharmacoepidemiol Drug Saf200918649750319326365
   PubMed Web of Science ®Google Scholar
• LonnEMBoschJDiazREffect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)Diabetes Care20133692466247423564916
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications TrialDiabetes19954489689837622004
   PubMed Web of Science ®Google Scholar
• ShichiriMKishikawaHOhkuboYWakeNLong-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patientsDiabetes Care200023Suppl 2B21B2910860187
   PubMed Web of Science ®Google Scholar
• BoussageonRBejan-AngoulvantTSaadatien-ElahiMEffect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trialsBMJ2011343d416921791495
   PubMed Web of Science ®Google Scholar
• ORIGIN trial investigatorsGilbertREMannJFBasal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trialDiabetologia20145771325133124771090
   PubMed Web of Science ®Google Scholar
• GreenwoodMWoodFThe Relation between the Cancer and Diabetes Death-ratesJ Hyg (Lond)19141418311820474569
   PubMedGoogle Scholar
• NicolucciAEpidemiological aspects of neoplasms in diabetesActa Diabetol2010472879520376506
   PubMed Web of Science ®Google Scholar
• KurtzhalsPSchafferLSorensenACorrelations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical useDiabetes2000496999100510866053
   PubMed Web of Science ®Google Scholar
• StammbergerIBubeADurchfeld-MeyerBDonaubauerHTroschauGEvaluation of the Carcinogenic Potential of Insulin Glargine (LANTUS) in Rats and MiceInt J Toxicol200221317117912055018
   PubMed Web of Science ®Google Scholar
• CurrieCJPooleCDGaleEAThe influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia20095291766177719572116
   PubMed Web of Science ®Google Scholar
• HemkensLGGrouvenUGunsterCRisk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort studyDiabetologia20095291732174419565214
   PubMed Web of Science ®Google Scholar
• JonassonJMLjungRTalbackMHaglundBGudbjornsdottirSSteineckGInsulin glargine use and short-term incidence of malignancies – a population-based follow-up study in SwedenDiabetologia20095291745175419588120
   PubMed Web of Science ®Google Scholar
• LjungRTalbackMHaglundBJonassonJMGudbjornsdottirSSteineckGInsulin glargine use and short-term incidence of breast cancer – a four-year population-based observationActa Oncol201251340040222497435
   PubMed Web of Science ®Google Scholar
• ColhounHMSDRN Epidemiology GroupUse of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology GroupDiabetologia20095291755176519603149
   PubMed Web of Science ®Google Scholar
• RosenstockJFonsecaVMcGillJBSimilar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label studyDiabetologia20095291971197319609501
   PubMed Web of Science ®Google Scholar
• HomePDLagarennePCombined randomised controlled trial experience of malignancies in studies using insulin glargineDiabetologia200952122499250619756478
   PubMed Web of Science ®Google Scholar
• BordeleauLYakubovichNDagenaisGRThe Association of Basal Insulin Glargine and/or n-3 Fatty Acids with Incident Cancers in Patients With DysglycemiaDiabetes Care20143751360136624574355
   PubMed Web of Science ®Google Scholar
• LiCZhaoGOkoroCAWenXJFordESBalluzLSPrevalence of Diagnosed Cancer According to Duration of Diagnosed Diabetes and Current Insulin Use Among US Adults With Diagnosed Diabetes: Findings from the 2009 Behavioral Risk Factor Surveillance SystemDiabetes Care20133661569157623300288
   PubMed Web of Science ®Google Scholar
• SenSHeYKoyaDKanasakiKCancer biology in diabetesJ Diabetes Investig201453251264
   PubMed Web of Science ®Google Scholar
• SommerfeldMRMullerGTschankGIn Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and its MetabolitesPLoS One201053e954020209060
   PubMed Web of Science ®Google Scholar